" class="no-js "lang="en-US"> Pfizer - Medtech Alert
Sunday, February 05, 2023
Pfizer | Pharmtech Focus

Pfizer

About Pfizer

Pfizer

Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and significantly improve lives.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.To learn more, visit www.pfizer.com.

Related Story

Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer

January 30 2023

Ribon Therapeutics, a clinical-stage biotechnology company developing therapeutics to target stress support pathways, today announced […]

Longevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases

January 18 2023

Gero today announced that it has entered into a research collaboration with Pfizer to apply Gero’s machine-learning […]

Pfizer Progresses its Oral Receptor into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity

December 21 2022

Sosei Group Corporation, the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design […]

ViroCell Strengthens Senior Management Team with Appointment of Nick Maishman as COO

November 22 2022

ViroCell Biologics, founded by the UK’s most prolific academic viral vector manufacturing team, today announces […]

Pfizer Completes Acquisition of Biohaven Pharmaceuticals

October 4 2022

Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding […]

CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development

September 21 2022

CytoReason today announced an extension of its multi-year partnership with Pfizer to use CytoReason’s artificial intelligence […]

Strata Oncology Announces Expansion of Clinical Collaboration with Pfizer for Strata PATH Trial into Early-Stage Cancer

September 14 2022

Strata Oncology, Inc. a next-generation precision oncology company enabling smarter and earlier cancer treatment, today […]

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent

August 30 2022

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the […]

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

August 9 2022

Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the […]

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design

July 28 2022

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, […]

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

June 27 2022

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and […]

Valneva and Pfizer Enter Into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

June 20 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced […]

Pfizer Completes Acquisition of ReViral

June 10 2022

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately […]

Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.

June 7 2022

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States […]

Pfizer to Acquire Biohaven Pharmaceuticals

May 11 2022

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the […]

Pfizer Names David M. Denton Chief Financial Officer

April 11 2022

Pfizer Inc. (NYSE: PFE) today announced that David M. Denton will join the Company as […]

Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment

February 25 2022

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE) today announced that the Committee […]

Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea

February 14 2022

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced positive top-line results […]

Pfizer and Alex Therapeutics Announce a Strategic Commercial Partnership to Provide Evidence-based Digital Therapeutics to Patients, Starting in Germany

January 31 2022

The Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics and world leading pharmaceutical company Pfizer have joined […]

Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19

January 5 2022

Pfizer Inc. (NYSE: PFE) announced that the U.S. government has committed to purchasing an additional 10 […]

Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply

December 21 2021

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement has been reached with the […]

Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY ® in Children 5 to under 12 Years of Age in the European Union

November 26 2021

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for […]

Zipline, Pfizer and BioNTech Collaboration Paves the Way for Automated, On-Demand Delivery of First mRNA COVID-19 Vaccines in Ghana

November 12 2021

Zipline, the global leader in instant logistics, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced […]

Pfizer Starts Study of mRNA-based Next Generation Flu Vaccine Program

September 28 2021

Pfizer Inc. (NYSE: PFE) announced today that the first participants have been dosed in a Phase […]

Pfizer and Biontech Expand Collaboration with U.S. to Provide 500 Million Additional Covid-19 Vaccine Doses at Not-for-profit Price for Donation to Poorest Countries

September 22 2021

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to expand their […]

Pfizer Announces Start of Phase 3 Clinical Trial in Adults for its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)

September 3 2021

Pfizer Inc. (NYSE:PFE) today announced the initiation of RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV […]

Pfizer Announces New Chief Business Innovation Officer Aamir Malik

August 27 2021

Pfizer Inc. (NYSE: PFE) today announced that Aamir Malik has joined the company as Executive […]

Pfizer to Acquire Trillium Therapeutics Inc.

August 24 2021

Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies […]

Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older

August 24 2021

Pfizer Inc.and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) approved […]

Xeljanz ® (Tofacitinib Citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

August 23 2021

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved XELJANZ ® (tofacitinib) […]

Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of Covid-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.

July 23 2021

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government […]

Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa

July 22 2021

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent […]

Pfizer Announces New Investor Relations Leader

July 19 2021

Pfizer Inc. (NYSE: PFE) today announced that Christopher Stevo has joined the company as Senior […]

U.S. FDA Approves Prevnar 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older

June 9 2021

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved […]

The MHRA Concludes Positive Safety Profile for Pfizer/BioNTech Vaccine in 12- to 15-year-olds

June 4 2021

An extension to the current UK approval of the Pfizer/BioNTech COVID-19 vaccine that allows its […]

Pfizer Initiates Study Exploring Coadministration of 20vPnC Vaccine Candidate

May 24 2021

Pfizer Inc. (NYSE: PFE) today announced that the first enrolled subjects have received their immunizations as […]

Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents

May 11 2021

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food […]

Pfizer and BioNTech Initiate BLA for FDA Approval of Vaccine

May 10 2021

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a Biologics License Application […]

Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games

May 6 2021

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a Memorandum of Understanding […]

Pfizer and BionTech achieve first authorization in the world for a vaccine to combat Covid-19

December 11 2020

Pfizer Inc. and BioNTech SE announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in […]